Nyxoah Completed 115 Implants In Its Dream US Pivotal Study, Submitted First Module In Modular PMA And Implanted First Patient In Acccess US Pivotal Study.

Nyxoah SA (NASDAQ:NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company has completed all 115 implants in its DREAM U.S. pivotal study, submitted the first module in the modular PMA submission and implanted the first patient in the ACCCESS U.S. pivotal study.